Influence of DOTA chelator position on biodistribution and targeting properties of 111In-labeled synthetic anti-HER2 affibody molecules

Bioconjugate Chemistry

Volumn 23, Issue 8, 2012, Pages 1661-1670

  Perols, Anna ^a   Honarvar, Hadis ^b   Strand, Joanna ^b   Selvaraju, Ramkumar ^c   Orlova, Anna ^c   Eriksson Karlström, Amelie ^a   Tolmachev, Vladimir ^b  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; MAMMALS; MOLECULAR IMAGING; MOLECULES; ONCOLOGY; PROTEINS;

AFFIBODY; AFFIBODY MOLECULES; BIODISTRIBUTIONS; CLEARANCE RATES; HEALTHY TISSUES; LABELINGS; MOLECULAR TARGETS; PROPERTY; TETRAACETIC ACID; TUMOR-TARGETING;

CHELATION;

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INDIUM 111; PEP 10415; PEP 11301; PEP 11302; TETRAXETAN; UNCLASSIFIED DRUG;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL LINE; CHELATION; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; DRUG STABILITY; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LYMPHOMA; MEDIATOR; MELTING POINT; MOLECULARLY TARGETED THERAPY; MOLECULE; MOUSE; NONHUMAN; PROTEIN FOLDING; RADIOCHEMISTRY; RAMOS LYMPHOMA; ROOM TEMPERATURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR BLOOD FLOW; TUMOR XENOGRAFT;

EID: 84865145661     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc3002369     Document Type: Article

References (33)

1. Yarden, Y. and Sliwkowski, M. X. (2001) Untangling the ErbB signalling network Nat. Rev. Mol. Cell Biol. 2, 127-137 (Pubitemid 33674041)
2. Graus-Porta, D., Beerli, R. R., Daly, J. M., and Hynes, N. E. (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling EMBO J. 16, 1647-1655 (Pubitemid 27151960)
3. Witton, C. J., Reeves, J. R., Going, J. J., Cooke, T. G., and Bartlett, J. M. (2003) Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer J. Pathol. 200, 290-297 (Pubitemid 36827302)
4. Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., and Slamon, D. J. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J. Clin. Oncol. 17, 2639
5. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., and Ullrich, A. 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244, 707-712 (Pubitemid 19147683)
6. Yu, D. and Hung, M. C. (2000) Overexpression of ErbB2 in cancer and ErbB2-targeting strategies Oncogene 19, 6115-6121 (Pubitemid 32059461)
7. Craft, N., Shostak, Y., Carey, M., and Sawyers, C. L. (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase Nat. Med. 5, 280-285 (Pubitemid 29124362)
8. Morote, J., de Torres, I., Caceres, C., Vallejo, C., Schwartz, S., Jr., and Reventos, J. (1999) Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer Int. J. Cancer 84, 421-425 (Pubitemid 29337131)
9. Verri, E., Guglielmini, P., Puntoni, M., Perdelli, L., Papadia, A., Lorenzi, P., Rubagotti, A., Ragni, N., and Boccardo, F. (2005) HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study Oncology 68, 154-161 (Pubitemid 41158970)
10. Carlsson, J. (2012) Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors. Tumour Biol. [Online early access].
11. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344, 783-792 (Pubitemid 32222155)
12. Woodard, L. E. and Nimmagadda, S. (2011) CXCR4-based imaging agents J. Nucl. Med. 52, 1665-1669
13. Tolmachev, V., Stone-Elander, S., and Orlova, A. (2010) Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls Lancet Oncol. 11, 992-1000
14. 111In-DOTA-ZIGF1R:4551 J. Nucl. Med. 53, 90-97
15. Nygren, P. A. (2008) Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold FEBS J. 275, 2668-2676
16. Lofblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., Stahl, S., and Frejd, F. Y. (2010) Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications FEBS Lett. 584, 2670-2680
17. Orlova, A., Magnusson, M., Eriksson, T. L., Nilsson, M., Larsson, B., Hoiden-Guthenberg, I., Widstrom, C., Carlsson, J., Tolmachev, V., Stahl, S., and Nilsson, F. Y. (2006) Tumor imaging using a picomolar affinity HER2 binding affibody molecule Cancer Res. 66, 4339-4348
18. Engfeldt, T., Renberg, B., Brumer, H., Nygren, P. A., and Karlstrom, A. E. (2005) Chemical synthesis of triple-labelled three-helix bundle binding proteins for specific fluorescent detection of unlabelled protein ChemBioChem 6, 1043-1050 (Pubitemid 40825345)
19. Orlova, A., Wallberg, H., Stone-Elander, S., and Tolmachev, V. (2009) On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model J. Nucl. Med. 50, 417-425
20. 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody Nucl. Med. Biol. 38, 1093-1102
21. Ahlgren, S. and Tolmachev, V. (2010) Radionuclide molecular imaging using Affibody molecules Curr. Pharm. Biotechnol. 11, 581-589
22. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule Eur. J. Nucl. Med. Mol. Imaging 34, 1843-1853 (Pubitemid 47599054)
23. Tolmachev, V., Hofstrom, C., Malmberg, J., Ahlgren, S., Hosseinimehr, S. J., Sandstrom, M., Abrahmsen, L., Orlova, A., and Graslund, T. (2010) HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [(m)Tc(CO)](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation Bioconjugate Chem. 21, 2013-2022
24. Ahlgren, S., Orlova, A., Rosik, D., Sandström, M., Sjöberg, A., Baastrup, B., Widmark, O., Fant, G., Feldwisch, J., and Tolmachev, V. (2008) Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules Bioconjugate Chem. 19, 235-243 (Pubitemid 351213855)
25. Malmberg, J., Perols, A., Varasteh, Z., Altai, M., Braun, A., Sandstrom, M., Garske, U., Tolmachev, V., Orlova, A., and Eriksson Karlstrom, A. (2012) Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with (111)In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts Eur. J. Nucl. Med. Mol. Imaging 39, 481-492
26. 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers Cancer Biother. Radiopharm. 23, 435-442
27. 68Ga-labeled affibody molecules J. Nucl. Med. 51, 892-897
28. 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount Eur. J. Nucl. Med. Mol. Imaging 37, 613-622
29. Kronqvist, N., Malm, M., Gostring, L., Gunneriusson, E., Nilsson, M., Hoiden Guthenberg, I., Gedda, L., Frejd, F. Y., Stahl, S., and Lofblom, J. (2011) Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules Protein Eng. Des. Sel. 24, 385-296
30. Lindborg, M., Cortez, E., Hoiden-Guthenberg, I., Gunneriusson, E., von Hage, E., Syud, F., Morrison, M., Abrahmsen, L., Herne, N., Pietras, K., and Frejd, F. Y. (2011) Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor beta in vivo J. Mol. Biol. 407, 298-315
31. Tolmachev, V. and Orlova, A. (2010) Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets Curr. Med. Chem. 17, 2636-2655
32. Froidevaux, S., Calame-Christe, M., Schuhmacher, J., Tanner, H., Saffrich, R., Henze, M., and Eberle, A. N. (2004) A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases J. Nucl. Med. 45, 116-123 (Pubitemid 47611617)
33. Eigenbrot, C., Ultsch, M., Dubnovitsky, A., Abrahmsén, L., and Härd, T. (2010) Structural basis for high-affinity HER2 receptor binding by an engineered protein Proc. Natl. Acad. Sci. U. S. A. 107, 15039-15044